Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2012 Mar;8(3):285-92. doi: 10.1586/eci.12.7.

Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence.

Author information

1
Department of Medicine, Sections of Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX 77030, USA. farrahk@bcm.edu

Abstract

Over the past few decades, neutrophils and macrophages had co-occupied center stage as the critical innate immune cells underlying the pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease and lung parenchymal destruction (i.e., emphysema). While chronic exposure to smoke facilitates the recruitment of innate immune cells into the lung, a clear role for adaptive immunity in emphysema has emerged. Evidence from human studies specifically point to a role for recruitment and activation of pathogenic lymphocytes and lung antigen-presenting cells in emphysema; similarly, animal models have confirmed a significant role for autoimumnity in progressive smoke-induced emphysema. Increased numbers of activated antigen-presenting cells, Th1 and Th17 cells, have been associated with smoke-induced lung inflammation and production of the canonical cytokines of these cells, IFN-γ and IL-17, correlates with disease severity. These exciting new breakthroughs could open new avenues for developing effective new therapies for smoke-induced emphysema.

PMID:
22390492
PMCID:
PMC3321360
DOI:
10.1586/eci.12.7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center